Adjuvant durvalumab

Phase 3Monoclonal antibody

Adjuvant durvalumab is one of 37 small molecule programs targeting Non-Small Cell Lung Cancer. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Small Cell Lung CancerActive, not recruiting

Non-Small Cell Lung CancerPhase 3

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Lenvima

Eisai

Preclinical

6 5

Imjudo

AstraZeneca

Preclinical

5 6

Vizimpro

Pfizer

Preclinical

4 7

Adjuvant durvalumab

EETOP IBCSG Partners Foundation

Phase 3

1 8

Gilotrif

Boehringer Ingelheim

Preclinical

12 9

Ofev

Boehringer Ingelheim

Preclinical

7 10

Immunotherapy

Bristol-Myers Squibb

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

Phase 3Recruiting

Non-Small Cell Lung Cancer

NCT06284317

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.

Recruiting·EETOP IBCSG Partners Foundation·Phase 3·NCT06284317·290 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Adjuvant durvalumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Adjuvant durvalumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Adjuvant durvalumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — ETOP IBCSG Partners Foundation company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 3[1]
Company: EETOP IBCSG Partners Foundation

Adjuvant durvalumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Non-Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News